2012

September 17, 2012
BTG to present at the UBS Global Life Sciences Conference

London, UK, 17 September 2012 BTG plc (LSE: BTG), the specialist healthcare company today announces that Andy Burrows, Director of Investor Relations will be presenting an overview of the company...

September 10, 2012
BTG to present at the Bank of America Merrill Lynch Global Healthcare Conference

London, UK, 10 September 2012 BTG plc (LSE: BTG), the specialist healthcare company today announces that Louise Makin, CEO will be presenting an overview of the company and its strategic...

September 05, 2012
CMS grants new prospective reimbursement for Voraxaze®

West Conshohocken, PA, 05 September 2012 New Technology Add-on Payment provides up to 50% of the cost of Voraxaze®prescribed in the inpatient setting BTG International Inc., the specialist...

August 08, 2012
BTG Announces Data from Phase IIb Study of AZD9773

London, UK, 08 August 2012 BTG plc (LSE: BTG), announces top-line data from a global double-blind Phase IIb study comparing the efficacy and safety of two doses of AZD9773 (CytoFab™) with...

July 17, 2012
BTG plc: Interim Management Statement

London, UK, 17 July 2012 BTG plc (LSE: BTG), the specialist healthcare company, today announces its interim management statement for the period from 1 April 2012 to 16 July 2012. Trading within...

Show 5102550100 per page
Top